These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

987 related articles for article (PubMed ID: 32625204)

  • 1. CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape.
    Rodriguez-Garcia A; Palazon A; Noguera-Ortega E; Powell DJ; Guedan S
    Front Immunol; 2020; 11():1109. PubMed ID: 32625204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment.
    Andrea AE; Chiron A; Mallah S; Bessoles S; Sarrabayrouse G; Hacein-Bey-Abina S
    Front Immunol; 2022; 13():830292. PubMed ID: 35211124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies.
    Zhang ZZ; Wang T; Wang XF; Zhang YQ; Song SX; Ma CQ
    Pharmacol Res; 2022 Jan; 175():106036. PubMed ID: 34920118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors.
    Grosser R; Cherkassky L; Chintala N; Adusumilli PS
    Cancer Cell; 2019 Nov; 36(5):471-482. PubMed ID: 31715131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment.
    Liu G; Rui W; Zhao X; Lin X
    Cell Mol Immunol; 2021 May; 18(5):1085-1095. PubMed ID: 33785843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mechanisms of resistance and escape to CAR-T cells].
    Grinda T; Brouard J; Tran D; Rubio MT
    Bull Cancer; 2021 Oct; 108(10S):S128-S140. PubMed ID: 34920795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.
    Sloas C; Gill S; Klichinsky M
    Front Immunol; 2021; 12():783305. PubMed ID: 34899748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Solid Tumors Challenges and New Insights of CAR T Cell Engineering.
    Tahmasebi S; Elahi R; Esmaeilzadeh A
    Stem Cell Rev Rep; 2019 Oct; 15(5):619-636. PubMed ID: 31161552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors.
    Donnadieu E; Dupré L; Pinho LG; Cotta-de-Almeida V
    J Leukoc Biol; 2020 Oct; 108(4):1067-1079. PubMed ID: 32620049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK/STAT-Dependent Chimeric Antigen Receptor (CAR) Expression: A Design Benefiting From a Dual AND/OR Gate Aiming to Increase Specificity, Reduce Tumor Escape and Affect Tumor Microenvironment.
    Khanali J; Azangou-Khyavy M; Boroomand-Saboor M; Ghasemi M; Niknejad H
    Front Immunol; 2021; 12():638639. PubMed ID: 34177890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR-macrophage versus CAR-T for solid tumors: The race between a rising star and a superstar.
    Chen K; Liu ML; Wang JC; Fang S
    Biomol Biomed; 2024 May; 24(3):465-476. PubMed ID: 37877819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Manipulating the tumor microenvironment by adoptive cell transfer of CAR T-cells.
    Gowrishankar K; Birtwistle L; Micklethwaite K
    Mamm Genome; 2018 Dec; 29(11-12):739-756. PubMed ID: 29987406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy.
    Lindo L; Wilkinson LH; Hay KA
    Front Immunol; 2020; 11():618387. PubMed ID: 33643299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment.
    Martinez M; Moon EK
    Front Immunol; 2019; 10():128. PubMed ID: 30804938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [T cell-based immunotherapies in solid tumors].
    Baulu E; Dougé A; Chuvin N; Bay JO; Depil S
    Bull Cancer; 2021 Oct; 108(10S):S96-S108. PubMed ID: 34920813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
    Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
    Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered cancer metabolism and implications for next-generation CAR T-cell therapies.
    Ramapriyan R; Vykunta VS; Vandecandelaere G; Richardson LGK; Sun J; Curry WT; Choi BD
    Pharmacol Ther; 2024 Jul; 259():108667. PubMed ID: 38763321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of exhaustion in CAR T cell therapy.
    Delgoffe GM; Xu C; Mackall CL; Green MR; Gottschalk S; Speiser DE; Zehn D; Beavis PA
    Cancer Cell; 2021 Jul; 39(7):885-888. PubMed ID: 34256903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
    Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
    Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solid Tumor Microenvironment Can Harbor and Support Functional Properties of Memory T Cells.
    Sullivan PM; Reed SJ; Kalia V; Sarkar S
    Front Immunol; 2021; 12():706150. PubMed ID: 34867942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.